Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead pays Parion Phase I development milestone

This article was originally published in Scrip

Executive Summary

Gilead Sciencesis to pay Parion Sciences a $5 million milestone after beginning a Phase I safety trial of GS9411. The epithelial sodium channel (ENaC) blocker, previously known as P-680, is an investigational compound designed to increase airway hydration for the treatment of pulmonary diseases. Gilead acquired the worldwide commercialisation rights to GS9411 for the treatment of pulmonary diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease and non-CF bronchiectasis, in August last year. Gilead will be responsible for the product's further primary development. The two companies are working together to develop other ENaC blocker-based drug candidates using Parion's ENaC-based chemistry platform.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts